NCT03945279 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

June 21, 2021

Study Completion Date

June 21, 2021

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

BIIB100

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (9)

Johns Hopkins University, Dept of Neurology, Baltimore

Research Site, Boston

Mayo Clinic Hospital, Jacksonville

University of South Florida, Tampa

Alliance for Multispecialty Research NOCCR/VRG, Knoxville

Research Site, St Louis

Research Site, Lincoln

Barrow Neurological Institute, Phoenix

University of California San Diego Medical Center, San Diego